Virtual Issue

Basic and Translational Biology of Lymphoma

Welcome to the inaugural Virtual Issue from Veterinary and Comparative Oncology (VCO). The concept of virtual issues is to tie together current and past articles that address a common theme or subject of interest to the veterinary and comparative oncology community. The current topic, lymphoma, was an easy choice for the inaugural issue as it remains one of the most common cancers, responsible for significant mortality and diminished quality of life in companion species. Over the last 4 years of VCO, several articles have been published dealing with both the advancement of our basic molecular and cellular understanding of this varied histology as well as our collective goal of improving the standard of care for treating lymphoma and the co-morbidities associated with it.

Despite advancements in our understanding of lymphoma in the past decade, curative therapies still elude the veterinary practitioner and the 1-year median survival hurdle still remains for the majority of our patients. It appears improvements in the application of traditional cytotoxic chemotherapy have progressed as far as possible with this disease and further advancements in the understanding of molecular targets on lymphoma cells are a necessary prerequisite to the discovery and application of novel therapeutics in the future. By way of example, the application of immunomodulatory techniques, such as monoclonal antibody therapy, represent the major advancement in the treatment and control of lymphoma in humans and the translation of this modality awaits further investigation in veterinary oncology. It is hoped the articles represented in this virtual issue help to inform the reader and create synergy within our readership leading to further advancement of the standard of care for this common and devastating malignancy.

-David Argyle and David Vail, Co-Editors, VCO

Table of Contents

Canine cutaneous epitheliotropic T-cell lymphoma: a review
Fontaine, J; Bovens, C; Bettenay, S, et al.

Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study
Lori, JC; Stein, TJ; Thamm, DH

Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases
Sorenmo, K; Overley, B; Krick, E, et al.

Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)-a veterinary cooperative oncology group (VCOG) consensus document
Vail, DM; Michels, GM; Khanna, C, et al.

High-mobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy
Meyer, A; Eberle, N; Bullerdiek, J, et al.

A toxicity study of low-dose rate half-body irradiation and chemotherapy in dogs with lymphoma
Lurie, DM; Kent, MS; Fry, MM, et al.

A feasibility study of low-dose total body irradiation for relapsed canine lymphoma
Brown, EM; Ruslander, DM; Azuma, C, et al.

Telornerase activity and telomerase reverse transcriptase catalytic subunit expression in canine lymphoma: correlation with Ki67 immunoreactivity
Renwick, MG; Argyle, DJ; Long, S, et al.

Human granulocyte-macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma
Turek, MM; Thamm, DH; Mitzey, A, et al.

NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging
Nadella, MVP; Kisseberth, WC; Nadella, KS, et al.